journal
https://read.qxmd.com/read/38521081/angela-vincent-a-pioneer-of-immune-mediated-disease
#1
JOURNAL ARTICLE
Jules Morgan
No abstract text is available yet for this article.
March 20, 2024: Lancet Neurology
https://read.qxmd.com/read/38513680/correction-to-lancet-neurol-2024-23-344-81
#2
(no author information available yet)
No abstract text is available yet for this article.
March 18, 2024: Lancet Neurology
https://read.qxmd.com/read/38499016/fluctuations-in-parkinson-s-disease-progress-and-challenges
#3
JOURNAL ARTICLE
Francisco Cardoso, Eduardo Tolosa
No abstract text is available yet for this article.
March 15, 2024: Lancet Neurology
https://read.qxmd.com/read/38499015/safety-and-efficacy-of-continuous-subcutaneous-levodopa-carbidopa-infusion-nd0612-for-parkinson-s-disease-with-motor-fluctuations-boundless-a-phase-3-randomised-double-blind-double-dummy-multicentre-trial
#4
JOURNAL ARTICLE
Alberto J Espay, Fabrizio Stocchi, Rajesh Pahwa, Alberto Albanese, Aaron Ellenbogen, Joaquim J Ferreira, Nir Giladi, Tanya Gurevich, Sharon Hassin-Baer, Jorge Hernandez-Vara, Stuart H Isaacson, Karl Kieburtz, Peter A LeWitt, Lydia Lopez-Manzanares, C Warren Olanow, Werner Poewe, Harini Sarva, Tami Yardeni, Liat Adar, Laurence Salin, Nelson Lopes, Nissim Sasson, Ryan Case, Olivier Rascol
BACKGROUND: Conventional oral levodopa therapy for the treatment of Parkinson's disease can be associated with variations in plasma concentrations. Levodopa infusion strategies might provide more consistent drug delivery and fewer motor fluctuations. We aimed to assess the safety and efficacy of a continuous 24 h/day subcutaneous infusion of ND0612 (a levodopa-carbidopa solution) compared with oral immediate-release levodopa-carbidopa for the treatment of motor fluctuations in people with Parkinson's disease...
March 15, 2024: Lancet Neurology
https://read.qxmd.com/read/38493796/addressing-neurological-burden-in-the-americas
#5
JOURNAL ARTICLE
Amy Tausch, Kiran T Thakur, Renato Oliveira E Souza
No abstract text is available yet for this article.
March 5, 2024: Lancet Neurology
https://read.qxmd.com/read/38493795/global-regional-and-national-burden-of-disorders-affecting-the-nervous-system-1990-2021-a-systematic-analysis-for-the-global-burden-of-disease-study-2021
#6
JOURNAL ARTICLE
(no author information available yet)
BACKGROUND: Disorders affecting the nervous system are diverse and include neurodevelopmental disorders, late-life neurodegeneration, and newly emergent conditions, such as cognitive impairment following COVID-19. Previous publications from the Global Burden of Disease, Injuries, and Risk Factor Study estimated the burden of 15 neurological conditions in 2015 and 2016, but these analyses did not include neurodevelopmental disorders, as defined by the International Classification of Diseases (ICD)-11, or a subset of cases of congenital, neonatal, and infectious conditions that cause neurological damage...
March 5, 2024: Lancet Neurology
https://read.qxmd.com/read/38493794/the-expanding-burden-of-neurological-disorders
#7
JOURNAL ARTICLE
Wolfgang Grisold
No abstract text is available yet for this article.
March 5, 2024: Lancet Neurology
https://read.qxmd.com/read/38373423/correction-to-lancet-neurol-2024-23-123
#8
(no author information available yet)
No abstract text is available yet for this article.
February 16, 2024: Lancet Neurology
https://read.qxmd.com/read/38364830/elevated-hope-for-patients-after-migraine-treatment-failure
#9
JOURNAL ARTICLE
Xiaonuo Xu, Liang Dong, Jiying Zhou
No abstract text is available yet for this article.
February 13, 2024: Lancet Neurology
https://read.qxmd.com/read/38364829/correction-to-lancet-neurol-2024-23-168-77
#10
(no author information available yet)
No abstract text is available yet for this article.
February 13, 2024: Lancet Neurology
https://read.qxmd.com/read/38280392/safety-and-efficacy-of-laquinimod-for-huntington-s-disease-legato-hd-a-multicentre-randomised-double-blind-placebo-controlled-phase-2-study
#11
JOURNAL ARTICLE
Ralf Reilmann, Karen E Anderson, Andrew Feigin, Sarah J Tabrizi, Blair R Leavitt, Julie C Stout, Paola Piccini, Robin Schubert, Pippa Loupe, Anna Wickenberg, Beth Borowsky, Gail Rynkowski, Rita Volkinshtein, Thomas Li, Juha-Matti Savola, Michael Hayden, Mark Forrest Gordon
BACKGROUND: Laquinimod modulates CNS inflammatory pathways thought to be involved in the pathology of Huntington's disease. Studies with laquinimod in transgenic rodent models of Huntington's disease suggested improvements in motor function, reduction of brain volume loss, and prolonged survival. We aimed to evaluate the safety and efficacy of laquinimod in improving motor function and reducing caudate volume loss in patients with Huntington's disease. METHODS: LEGATO-HD was a multicentre, double-blind, placebo-controlled, phase 2 study done at 48 sites across ten countries (Canada, Czech Republic, Germany, Italy, Netherlands, Portugal, Russia, Spain, UK, and USA)...
January 24, 2024: Lancet Neurology
https://read.qxmd.com/read/38280391/brain-capital-is-crucial-for-global-sustainable-development
#12
LETTER
Harris A Eyre, William Hynes, Rym Ayadi, Facundo Manes, Pawel Swieboda
No abstract text is available yet for this article.
January 24, 2024: Lancet Neurology
https://read.qxmd.com/read/38280390/laquinimod-huntington-s-disease-and-disease-modification
#13
JOURNAL ARTICLE
Tiago A Mestre
No abstract text is available yet for this article.
January 24, 2024: Lancet Neurology
https://read.qxmd.com/read/38513673/getting-inside-the-head-of-edinburgh-fringe-performers
#14
JOURNAL ARTICLE
Peter Ranscombe
No abstract text is available yet for this article.
April 2024: Lancet Neurology
https://read.qxmd.com/read/38508840/correction-to-lancet-neurol-2023-22-1026-47
#15
(no author information available yet)
No abstract text is available yet for this article.
April 2024: Lancet Neurology
https://read.qxmd.com/read/38508839/correction-to-lancet-neurol-2021-20-448-59
#16
(no author information available yet)
No abstract text is available yet for this article.
April 2024: Lancet Neurology
https://read.qxmd.com/read/38508838/genetics-of-migraine-complexity-implications-and-potential-clinical-applications
#17
REVIEW
Heidi G Sutherland, Bronwyn Jenkins, Lyn R Griffiths
Migraine is a common neurological disorder with large burden in terms of disability for individuals and costs for society. Accurate diagnosis and effective treatments remain priorities. Understanding the genetic factors that contribute to migraine risk and symptom manifestation could improve individual management. Migraine has a strong genetic basis that includes both monogenic and polygenic forms. Some distinct, rare, familial migraine subtypes are caused by pathogenic variants in genes involved in ion transport and neurotransmitter release, suggesting an underlying vulnerability of the excitatory-inhibitory balance in the brain, which might be exacerbated by disruption of homoeostasis and lead to migraine...
April 2024: Lancet Neurology
https://read.qxmd.com/read/38508837/dysphagia-after-stroke-research-advances-in-treatment-interventions
#18
REVIEW
Bendix Labeit, Emilia Michou, Michaela Trapl-Grundschober, Sonja Suntrup-Krueger, Paul Muhle, Philip M Bath, Rainer Dziewas
After a stroke, most patients have dysphagia, which can lead to aspiration pneumonia, malnutrition, and adverse functional outcomes. Protective interventions aimed at reducing these complications remain the cornerstone of treatment. Dietary adjustments and oral hygiene help mitigate the risk of aspiration pneumonia, and nutritional supplementation, including tube feeding, might be needed to prevent malnutrition. Rehabilitative interventions aim to enhance swallowing function, with different behavioural strategies showing promise in small studies...
April 2024: Lancet Neurology
https://read.qxmd.com/read/38508836/secondary-stroke-prevention-in-people-with-atrial-fibrillation-treatments-and-trials
#19
REVIEW
David J Seiffge, Virginia Cancelloni, Lorenz Räber, Maurizio Paciaroni, Andreas Metzner, Paulus Kirchhof, Urs Fischer, David J Werring, Ashkan Shoamanesh, Valeria Caso
Atrial fibrillation is one of the most common cardiac arrhythmias and is a major cause of ischaemic stroke. Recent findings indicate the importance of atrial fibrillation burden (device-detected, subclinical, or paroxysmal and persistent or permanent) and whether atrial fibrillation was known before stroke onset or diagnosed after stroke for the risk of recurrence. Secondary prevention in patients with atrial fibrillation and stroke aims to reduce the risk of recurrent ischaemic stroke. Findings from randomised controlled trials assessing the optimal timing to introduce direct oral anticoagulant therapy after a stroke show that early start (ie, within 48 h for minor to moderate strokes and within 4-5 days for large strokes) seems safe and could reduce the risk of early recurrence...
April 2024: Lancet Neurology
https://read.qxmd.com/read/38508835/safety-and-efficacy-of-givinostat-in-boys-with-duchenne-muscular-dystrophy-epidys-a-multicentre-randomised-double-blind-placebo-controlled-phase-3-trial
#20
RANDOMIZED CONTROLLED TRIAL
Eugenio Mercuri, Juan J Vilchez, Odile Boespflug-Tanguy, Craig M Zaidman, Jean K Mah, Nathalie Goemans, Wolfgang Müller-Felber, Erik H Niks, Ulrike Schara-Schmidt, Enrico Bertini, Giacomo P Comi, Katherine D Mathews, Laurent Servais, Krista Vandenborne, Jessika Johannsen, Sonia Messina, Stefan Spinty, Laura McAdam, Kathryn Selby, Barry Byrne, Chamindra G Laverty, Kevin Carroll, Giulia Zardi, Sara Cazzaniga, Nicoletta Coceani, Paolo Bettica, Craig M McDonald
BACKGROUND: Duchenne muscular dystrophy, the most common childhood muscular dystrophy, is caused by dystrophin deficiency. Preclinical and phase 2 study data have suggested that givinostat, a histone deacetylase inhibitor, might help to counteract the effects of this deficiency. We aimed to evaluate the safety and efficacy of givinostat in the treatment of Duchenne muscular dystrophy. METHODS: This multicentre, randomised, double-blind, placebo-controlled, phase 3 trial was done at 41 tertiary care sites in 11 countries...
April 2024: Lancet Neurology
journal
journal
20188
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.